-
今开：--
昨收：--
-
今日区间：--
52周区间：--
-
成交量：--
成交额：--
-
市 值：--
市盈率：--
-
振幅：
每股收益：
成交量
董事会
- Baron Jean Stéphenne
- Baron Jean St phenne currently works at Recherche Et Industrie Therapeutiques, as Chairman & Chief Executive Officer from 1974, CureVac SE, as Chairman-Supervisory Board from 2020, Universit Catholique de Louvain, as Chairman, Nanocyl SA, as Chairman from 2012, Vesalius Biocapital II SA SICAR, as Chairman, University Foundation, as Chairman, BePharBel Manufacturing SA, as Chairman, Innoste SA, as Chairman, CureVac NV, as Chairman-Supervisory Board from 2015, N-Side SA, as Director from 2015, Opus-Invest NV, as Director, Fondation Belge Contre Le Cancer, as Director, Vaxxilon AG, as Director, and Belgian Foundation Against Cancer, as Director. Mr. St phenne also formerly worked at Gsk Biologicals, as Chairman, President & Chief Executive Officer from 2002 to 2012, TiGenix NV, as Chairman, GlaxoSmithKline Biologicals SA, as Chairman & President-Biologicals in 2012, OncoDNA SA, as Chairman, Aseptic Technologies SA, as Chairman, Henogen SA, as Chairman, Vesalius Biocapital I SA SICAR, as Chairman, Sparkoh CV, as Chairman, Bone Therapeutics SA, as Chairman, Wallon Institute for Life Lead Sciences, as Chairman, BioWin ASBL, as Chairman, IntegraGen SA, as Chairman-Supervisory Board, Ion Beam Applications SA, as Director from 2000 to 2011, Groupe Bruxelles Lambert SA, as Independent Non-Executive Director, BNP Paribas Fortis SA, as Director, Federation of Enterprises in Belgium, as Director, BESIX Group NV, as Director, Auguria Residential Real Estate Fund (Brussels), as Director, Uteron Pharma SA, as Director, Theravectys SAS, as Independent Director, and Union Wallonne des Entreprises, as President from 1997 to 2000. Mr. St phenne received his undergraduate degree in 1972 from Facult Universitaire des Sciences Agronomiques de Gembloux and undergraduate degree from Universit Catholique de Louvain.
-
- Mathias Hothum
- Mathias Hothum is the founder of Hmm Consulting. Current jobs include Deputy Chairman of the Supervisory Board at Heidelberg Pharma AG since 2020, Chairman of the Supervisory Board at GEUDER AG, Managing Director at dievini Hopp BioTech holding GmbH & Co. KG , Managing Director at dievini Verwaltungs GmbH, Co-Managing Director at TSG 1899 Hoffenheim Fu ball-Besitzgesellschaft mbH & Co. KG, Non-Executive Director at Immatics NV since 2023, Managing Director at OH Venture Management GmbH, Member of the Supervisory Board at CureVac SE, Apogenix AG, Molecular Health GmbH, Novaliq GmbH, and CureVac NV since 2015. Former jobs include Non-Executive Director at AC Immune SA, Director at Weinheim 216 GmbH & Co. KG, Director at Joimax GmbH, Co-Managing Director at Drug Delivery Systems Beteiligungs GmbH, and Member of the Supervisory Board at Molecular Health, Inc. Education includes undergraduate studies at the University of Mannheim and a doctorate from Otto-von-Guericke-Universit t Magdeburg.
-
- Craig Allen Tooman
- Craig Allen Tooman was the founder of Stockbourne LLC, founded in 2011, and served as Principal from 2011 to 2012. Current jobs include Director at Silence Therapeutics, Inc. since 2021, Director at Verte Therapeutics LLC, Member-Supervisory Board at CureVac SE since 2019, and Independent Member-Supervisory Board at CureVac NV since 2019. Former jobs include President, Chief Executive Officer & Director at Aratana Therapeutics, Inc. in 2019; Chief Executive Officer at Avanzar Medical, Inc. from 2012 to 2014; President, CEO & Executive Director at Silence Therapeutics Plc from 2022 to 2025; Independent Director at InSite Vision, Inc. from 2011 to 2015; Director at Xanodyne Pharmaceuticals, Inc.; Director at Aratana Therapeutics NV; Chief Operating & Financial Officer, Director at Vyome Therapeutics, Inc. from 2019 to 2021; Director at Vet Therapeutics, Inc.; Director at ViroVet NV; Independent Non-Executive Director at Ondine Biomedical, Inc. from 2021 to 2024; Chief Financial Officer, Executive VP & Head-IR at Enzon Pharmaceuticals, Inc. in 2010; Vice President-Investor Relations at Pharmacia & Upjohn, Inc.; SVP-Strategic Planning & Corporate Communications at ILEX Oncology, Inc. in 2005; Chief Financial Officer & Senior Vice President at Ikaria, Inc. from 2010 to 2011; Vice President-Investor Relations at Pharmacia Corp. Education includes an MBA from The University of Chicago and undergraduate studies at Kalamazoo College.
-
- Klaus Schollmeier
- Currently, Klaus Schollmeier is Chairman at Anergis SA, Pcovery ApS (since 2015), Eternygen GmbH, Inthera Bioscience AG (Chairman-Supervisory Board), and TACALYX GmbH (since 2020). He is a Member-Supervisory Board at Heidelberg Pharma AG (starting 2025), Minaris Regenerative Medicine GmbH, Novaliq GmbH, and an Independent Member-Supervisory Board at CureVac NV (since 2022). Formerly, Dr. Schollmeier was Chief Executive Officer at SuppreMol GmbH from 2013 to 2015, Chairman at Santhera Pharmaceuticals Holding AG from 2011 to 2012, Managing Director at ING BHF-Bank AG, Senior Director-Biotechnology at BASF Bioresearch Corp. from 1989 to 1993, Director at Graffinity Pharmaceuticals AG, Principal at Abbott GmbH (Germany) and Knoll AG, Research Associate Professor-Medical School at Boston University, General Manager at BASF Pharma from 1996 to 1998, and Member-Supervisory Board at Modra Pharmaceuticals BV. Education includes a doctorate from Heinrich-Heine-Universit t D sseldorf conferred in 1991.
-
- Michael Brosnan
- Michael Brosnan currently works at CureVac SE, as Member-Supervisory Board, Vifor Fresenius Medical Care Renal Pharma Ltd., as Member-Supervisory Board, Daimler Truck AG, as Member-Supervisory Board, CureVac NV, as Independent Member-Supervisory Board from 2023, and Daimler Truck Holding AG, as Independent Member-Supervisory Board from 2021. Mr. Brosnan also formerly worked at Fresenius Medical Care AG, as Chief Financial Officer from 2010 to 2019, Fresenius Medical Care Holdings, Inc., as Chief Financial Officer & Executive Vice President from 2003 to 2009, KPMG LLP, as Audit Partner from 1988 to 1993, Polaroid Corp., as Senior Controller-Commercial Imaging Group from 1994 to 1996, Fresenius Medical Care Management AG, as Chief Financial Officer from 2010 to 2019, KPMG AG Wirtschaftspr fungsgesellschaft, as Audit Partner from 1978 to 1993, High Voltage Engineering Corp., as Vice President-Financial Operations from 1997 to 1998, and MorphoSys AG, as Member-Supervisory Board from 2018 to 2024. Mr. Brosnan received his undergraduate degree in 1978 from Northeastern University.
-
- Birgit Hofmann
- Mr. Birgit Hofmann is on the Board of Directors at CureVac NV and evgedem Ein- und Verkaufsgenossenschaft der Metzgermeister eG.
-
- Mehdi Shahidi
- Mehdi Shahidi currently works at Petalion Therapeutics Ltd., as Chairman & Chief Executive Officer, Medicxi Ventures (Jersey) Ltd., as Venture Partner, Aivivo Ltd., as Chief Medical Expert from 2022, and CureVac NV, as Independent Member-Supervisory Board from 2024. Dr. Shahidi also formerly worked at SCS Boehringer Ingelheim Comm.V, as Chief Medical Officer, SVP & Global Head-Medicine.
-